C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: Is there any threat for chronic rejection development?

Mariano Ferraresso, Luciana Ghio, Alberto Edefonti, Sarà Vigano, Luigi Boschiero, Luisa Berardinelli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The clinical management of cyclosporine has evolved greatly during the last decade thanks to the use of pharmacokinetic (PK) studies which confirmed the dose relationship between drug exposure and its biological effects. Therefore, cyclosporine PK monitoring during the early phase of the post-transplant period became essential to avoid over or underexposure to the drug thus preventing the risk of nephrotoxicity or acute rejection episodes. More recently, a simple PK determination based on cyclosporine blood concentration measured 2 h after the morning dose, has proven to be very effective for monitoring cyclosporine exposure in the early postoperative period. In this paper, the authors present a set of PK profiles obtained from a stable, long-term pediatric kidney transplant population and correlate these parameters with the risk of chronic rejection development. The study shows how cyclosporine monitoring based on the sole trough level determination misled a correct therapeutic behavior, as revealed by the PK parameters that were constantly below the therapeutic threshold in a small patient cohort who eventually developed chronic rejection. The C2 determination should be considered as the gold standard for cyclosporine monitoring in long-term pediatric recipients.

Original languageEnglish
Pages (from-to)328-331
Number of pages4
JournalPediatric Transplantation
Volume9
Issue number3
DOIs
Publication statusPublished - Jun 2005

Fingerprint

Cyclosporine
Pediatrics
Kidney
Pharmacokinetics
Transplants
Postoperative Period
Pharmaceutical Preparations
Transplant Recipients
Therapeutics
Population

Keywords

  • C2 monitoring
  • Chronic rejection
  • Cyclosporine
  • Neoral
  • Pediatric kidney transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients : Is there any threat for chronic rejection development? / Ferraresso, Mariano; Ghio, Luciana; Edefonti, Alberto; Vigano, Sarà; Boschiero, Luigi; Berardinelli, Luisa.

In: Pediatric Transplantation, Vol. 9, No. 3, 06.2005, p. 328-331.

Research output: Contribution to journalArticle

Ferraresso, Mariano ; Ghio, Luciana ; Edefonti, Alberto ; Vigano, Sarà ; Boschiero, Luigi ; Berardinelli, Luisa. / C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients : Is there any threat for chronic rejection development?. In: Pediatric Transplantation. 2005 ; Vol. 9, No. 3. pp. 328-331.
@article{659772254f33456eb46af9614079a700,
title = "C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: Is there any threat for chronic rejection development?",
abstract = "The clinical management of cyclosporine has evolved greatly during the last decade thanks to the use of pharmacokinetic (PK) studies which confirmed the dose relationship between drug exposure and its biological effects. Therefore, cyclosporine PK monitoring during the early phase of the post-transplant period became essential to avoid over or underexposure to the drug thus preventing the risk of nephrotoxicity or acute rejection episodes. More recently, a simple PK determination based on cyclosporine blood concentration measured 2 h after the morning dose, has proven to be very effective for monitoring cyclosporine exposure in the early postoperative period. In this paper, the authors present a set of PK profiles obtained from a stable, long-term pediatric kidney transplant population and correlate these parameters with the risk of chronic rejection development. The study shows how cyclosporine monitoring based on the sole trough level determination misled a correct therapeutic behavior, as revealed by the PK parameters that were constantly below the therapeutic threshold in a small patient cohort who eventually developed chronic rejection. The C2 determination should be considered as the gold standard for cyclosporine monitoring in long-term pediatric recipients.",
keywords = "C2 monitoring, Chronic rejection, Cyclosporine, Neoral, Pediatric kidney transplantation",
author = "Mariano Ferraresso and Luciana Ghio and Alberto Edefonti and Sar{\`a} Vigano and Luigi Boschiero and Luisa Berardinelli",
year = "2005",
month = "6",
doi = "10.1111/j.1399-3046.2005.00317.x",
language = "English",
volume = "9",
pages = "328--331",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients

T2 - Is there any threat for chronic rejection development?

AU - Ferraresso, Mariano

AU - Ghio, Luciana

AU - Edefonti, Alberto

AU - Vigano, Sarà

AU - Boschiero, Luigi

AU - Berardinelli, Luisa

PY - 2005/6

Y1 - 2005/6

N2 - The clinical management of cyclosporine has evolved greatly during the last decade thanks to the use of pharmacokinetic (PK) studies which confirmed the dose relationship between drug exposure and its biological effects. Therefore, cyclosporine PK monitoring during the early phase of the post-transplant period became essential to avoid over or underexposure to the drug thus preventing the risk of nephrotoxicity or acute rejection episodes. More recently, a simple PK determination based on cyclosporine blood concentration measured 2 h after the morning dose, has proven to be very effective for monitoring cyclosporine exposure in the early postoperative period. In this paper, the authors present a set of PK profiles obtained from a stable, long-term pediatric kidney transplant population and correlate these parameters with the risk of chronic rejection development. The study shows how cyclosporine monitoring based on the sole trough level determination misled a correct therapeutic behavior, as revealed by the PK parameters that were constantly below the therapeutic threshold in a small patient cohort who eventually developed chronic rejection. The C2 determination should be considered as the gold standard for cyclosporine monitoring in long-term pediatric recipients.

AB - The clinical management of cyclosporine has evolved greatly during the last decade thanks to the use of pharmacokinetic (PK) studies which confirmed the dose relationship between drug exposure and its biological effects. Therefore, cyclosporine PK monitoring during the early phase of the post-transplant period became essential to avoid over or underexposure to the drug thus preventing the risk of nephrotoxicity or acute rejection episodes. More recently, a simple PK determination based on cyclosporine blood concentration measured 2 h after the morning dose, has proven to be very effective for monitoring cyclosporine exposure in the early postoperative period. In this paper, the authors present a set of PK profiles obtained from a stable, long-term pediatric kidney transplant population and correlate these parameters with the risk of chronic rejection development. The study shows how cyclosporine monitoring based on the sole trough level determination misled a correct therapeutic behavior, as revealed by the PK parameters that were constantly below the therapeutic threshold in a small patient cohort who eventually developed chronic rejection. The C2 determination should be considered as the gold standard for cyclosporine monitoring in long-term pediatric recipients.

KW - C2 monitoring

KW - Chronic rejection

KW - Cyclosporine

KW - Neoral

KW - Pediatric kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=20344370753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344370753&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3046.2005.00317.x

DO - 10.1111/j.1399-3046.2005.00317.x

M3 - Article

C2 - 15910389

AN - SCOPUS:20344370753

VL - 9

SP - 328

EP - 331

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 3

ER -